Ito Mitsuru, Deguchi-Horiuchi Hanna, Takahashi Sawako, Hisakado Mako, Kohsaka Kazuyoshi, Nishihara Eijun, Fukata Shuji, Nishikawa Mitsushige, Miyauchi Akira, Akamizu Takashi
Center for Excellence in Thyroid Care, Kuma Hospital, Hyogo 650-0011, Japan.
Endocr J. 2025 Jan 6;72(1):69-77. doi: 10.1507/endocrj.EJ24-0259. Epub 2024 Oct 23.
We and other investigators reported that mild TSH suppression with levothyroxine (LT) was needed to achieve normal free triiodothyronine (FT) levels and metabolic euthyroid state in athyreotic patients. Consequently, management methods based on thyroid tissue volume have been implemented for patients receiving LT at the Kuma Hospital. This retrospective study examined the composition of the thyroid hormone measurement items (serum-free thyroxine [FT], FT, and FT + FT) in patients receiving LT monotherapy. According to the etiology of hypothyroidism, 36% of the 25,523 patients included in this study underwent total thyroidectomy (TT). Thirteen percent and 14% had undergone I treatment for hyperthyroidism (RIT) and partial thyroidectomy (PT), respectively. Moreover, 37% of patients had received non-invasive treatment (NIT). The proportion of patients who underwent only FT measurements was higher (TT, 93%; RIT, 61%) in the first two groups, whereas the proportion of patients who underwent only FT measurements was higher (PT, 50%; NIT, 65%) in the remaining two groups. Only FT measurements were performed in 58% of patients. Only FT measurements were performed in 34% of patients. The serum TSH levels were suppressed in nearly half of the patients (46%). Thus, FT was the major thyroid hormone measured in patients receiving LT treatment, and the serum TSH levels were suppressed in nearly half of the patients. This may be attributed to the management guidelines at our hospital, a specialized facility for thyroid disease, wherein half of the patients present are athyreotic or have atrophic thyroid glands after TT or RIT.
我们和其他研究者报告称,对于甲状腺切除术后患者,需要使用左甲状腺素(LT)进行轻度促甲状腺激素(TSH)抑制,以实现游离三碘甲状腺原氨酸(FT)水平正常和代谢正常的甲状腺功能状态。因此,熊本医院已对接受LT治疗的患者实施了基于甲状腺组织体积的管理方法。这项回顾性研究调查了接受LT单一疗法患者的甲状腺激素测量项目(血清游离甲状腺素[FT]、FT以及FT+FT)的构成情况。根据甲状腺功能减退的病因,本研究纳入的25523例患者中,36%接受了甲状腺全切术(TT)。分别有13%和14%的患者因甲状腺功能亢进接受了碘治疗(RIT)和甲状腺部分切除术(PT)。此外,37%的患者接受了非侵入性治疗(NIT)。前两组中仅进行FT测量的患者比例较高(TT组为93%;RIT组为61%),而后两组中仅进行FT测量的患者比例较高(PT组为50%;NIT组为65%)。58%的患者仅进行了FT测量。34%的患者仅进行了FT测量。近一半的患者(46%)血清TSH水平受到抑制。因此,FT是接受LT治疗患者主要检测的甲状腺激素,且近一半患者的血清TSH水平受到抑制。这可能归因于我们医院(一家甲状腺疾病专科医院)的管理指南,在本院就诊的患者中有一半是甲状腺切除术后或接受RIT后甲状腺无功能或甲状腺萎缩的患者。